Lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) are both subtypes of non-small cell lung cancer (NSCLC), yet typically present a wide disparity in patient prognosis. Understanding the molecular underpinnings of these different outcomes requires transcriptomic studies at the single cell level.

• Comparative analysis identifies NSCLC tumor-specific cell types that had been previously annotated as rare cell types.
• Built-in multiplexing capability allows profiling of clinical samples at scale, for up to 1M cells on a single chip.
• Robust fixation protocol expands sample access for multi-site translational studies without compromising data quality.